3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
115
Urinary Bladder Neoplasms
56
Carcinoma, Non-Small-Cell Lung
53
Cholangiocarcinoma
33
Biliary Tract Neoplasms
32
Neoplasm Metastasis
30
Ovarian Neoplasms
29
Lymphoma, Large B-Cell, Diffuse
27
Breast Neoplasms
25
Neoplasms
24
Lung Neoplasms
24
Carcinoma, Transitional Cell
23
Triple Negative Breast Neoplasms
22
Nasopharyngeal Carcinoma
21
Colorectal Neoplasms
20
Non-Muscle Invasive Bladder Neoplasms
19
Recurrence
17
Fallopian Tube Neoplasms
16
Gallbladder Neoplasms
15
Sarcoma
13
Bile Duct Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Hodgkin Disease
10
Lymphoma
9
Adenocarcinoma
9
Uterine Cervical Neoplasms
8
Stomach Neoplasms
7
Lymphoma, Non-Hodgkin
7
Endometrial Neoplasms
7
Nasopharyngeal Neoplasms
6
Interventions
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Nivolumab
1
Mitomycin
1
Human Papillomavirus DNA Tests
1
Gemcitabine
1
Fluorouracil
1
Colposcopy
1
Cisplatin
1
Biopsy
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
Gemcitabine
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled